Stockscreener 앱 받기
120.28
2.43%
-2.99
전일 마감가:
$123.27
열려 있는:
$124.45
하루 거래량:
4.76M
Relative Volume:
1.54
시가총액:
$23.25B
수익:
$29.52M
순이익/손실:
$-567.06M
주가수익비율:
-32.86
EPS:
-3.66
순현금흐름:
$-551.11M
1주 성능:
+1.38%
1개월 성능:
+55.08%
6개월 성능:
+213.23%
1년 성능:
+201.45%
1일 변동 폭
$119.61
$124.49
1주일 범위
$113.33
$124.49
52주 변동 폭
$29.17
$124.49
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
415-766-3638
주소
700 SAGINAW DR, REDWOOD CITY, CA
RVMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
120.28 | 23.83B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-09-12 | 재개 | Raymond James | Strong Buy |
| 2025-09-05 | 개시 | Truist | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-08-15 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Revolution Medicines gets FDA Breakthrough Therapy status for daraxonrasib - MSN
Revolution Medicines Sees Unusually High Options Volume (NASDAQ:RVMD) - MarketBeat
Aug Wrap: Should I hold or sell INNEOVA Holdings Limited nowOptions Play & Verified Technical Trade Signals - baoquankhu1.vn
Revolution Medicines’ Stock Jumped On RAS Drug Hopes And Buyout Chatter - Finimize
Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year HighStill a Buy? - MarketBeat
Revolution Medicines stock hits all-time high at 121.62 USD By Investing.com - Investing.com South Africa
Revolution Medicines stock hits all-time high at 121.62 USD - Investing.com
Revolution Medicines (RVMD) Price Target Increased by 10.10% to 92.82 - Nasdaq
Merck reportedly in talks to buy Revolution in huge $28–32bn deal - BioXconomy
What sentiment indicators say about Revolution Medicines Inc. stockPortfolio Allocation Tips & We Spotted the Next Tesla – See Inside - bollywoodhelpline.com
Revolution Medicines (BIT:1RVMD) Price Target Increased by 13.08% to 76.84 - Nasdaq
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B - Stocktwits
Looking At Revolution Medicines's Recent Unusual Options Activity - Benzinga
J.P. Morgan: Revolution Awaits Key Readout As Merck Takeover Rumors Swirl - Citeline News & Insights
Mizuho Raises Price Target for RVMD to $143, Maintains Outperfor - GuruFocus
Merck (MRK) Acquisition Talks with Revolution Medicines: Analyst's Perspective - GuruFocus
Revolution Medicines declines to comment on M&A speculation at conference - MSN
Revolution Medicines (RVMD) Shares Dip Amid Merck Acquisition Ru - GuruFocus
Revolution Medicines: Dominant Pancreatic Cancer Position, Expanding RAS Franchise, and 2026 Catalyst Funnel Support Buy Rating - TipRanks
Revolution Medicines CEO Addresses Investor Questions on Merck Acquisition at J.P. Morgan Healthcare Conference - geneonline.com
Revolution Medicines stock gains as Stifel highlights strong PDAC position By Investing.com - Investing.com India
Revolution Medicines stock gains as Stifel highlights strong PDAC position - Investing.com
$30B ‘might not be enough’ for Revolution Medicines, says Stifel - TipRanks
With a grin — and tight lips — Revolution Medicines’ CEO faces questions about acquisition - statnews.com
RVMD Projects Significant Growth with Solid Financial Position b - GuruFocus
Revolution Medicines (RVMD) CEO Cancels Conference Appearance - GuruFocus
RVMD: Late-stage RAS-targeted therapies advance, with new resistance-overcoming drugs entering trials in 2026 - TradingView — Track All Markets
Revolution Medicines CEO says not commenting on ‘rumors or speculation’ - TipRanks
Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus - TechStock²
AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense - sharewise.com
Tema Etfs LLC Has $5.93 Million Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Pharmaceutical Giants Eye Revolution Medicines with $23 Billion Market Cap Amid Oncology M&A Surge - geneonline.com
Revolution Medicines: Take The Win And Sell Following Large Move Sparked By Buyout Rumors - Seeking Alpha
JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree - Pharmaceutical Technology
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Rating of "Buy" by Analysts - MarketBeat
Merck Could Strike 30 Billion Deal for Revolution Medicines - Oncodaily
Merck in Talks to Acquire Revolution Medicines for Approximately $30 Billion - Intellectia AI
RVMD stock hits a record high on rumored takeover interest - MSN
Sandisk, Bloom Energy, And Oklo Are Among the Top 10 Large-Cap Gainers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio? - Benzinga
AbbVie denies it’s in talks to buy Revolution Medicines. Both stocks are falling. - MSN
AbbVie in advanced talks to buy cancer drugmaker Revolution Medicines, shares jump nearly 30% - MSN
AbbVie says not in talks to buy Revolution Medicinesreport - MSN
Merck (MRK) Eyes $30 Billion Acquisition of Revolution Medicines - GuruFocus
AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research - Finviz
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK - TechStock²
Erasca Stock Surges as Market Eyes Revolution Medicines Acquisition - StocksToTrade
A Look At Revolution Medicines (RVMD) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Revolution Medicines shares climb after FDA grants Orphan Drug Designation for pancreatic cancer treatment - MSN
Revolution Medicines stock jumps on Merck buyout buzz and an FDA breakthrough tag — what to watch Monday - TechStock²
Revolution Medicines gains breakthrough therapy status for zoldonrasib - MSN
Is It Too Late To Consider Revolution Medicines (RVMD) After Its Recent 50% Weekly Surge? - Yahoo Finance
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.92%
4.73%
자본화:
|
볼륨(24시간):